Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
Division of Nephrology, Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Kidney360. 2022 Apr 18;3(6):1003-1010. doi: 10.34067/KID.0007582021. eCollection 2022 Jun 30.
Worsening serum creatinine is common during treatment of acute decompensated heart failure (ADHF). A possible contributor to creatinine increase is diuresis-induced changes in volume of distribution (VD) of creatinine as total body water (TBW) contracts around a fixed mass of creatinine. Our objective was to better understand the filtration and nonfiltration factors driving change in creatinine during ADHF.
Participants in the ROSE-AHF trial with baseline to 72-hour serum creatinine; net fluid output; and urinary KIM-1, NGAL, and NAG were included (=270). Changes in VD were calculated by accounting for measured input and outputs from weight-based calculated TBW. Changes in observed creatinine (Cr) were compared with predicted changes in creatinine after accounting for alterations in VD and non-steady state conditions using a kinetic GFR equation (Cr).
When considering only change in VD, the median diuresis to elicit a ≥0.3 mg/dl rise in creatinine was -7526 ml (IQR, -5932 to -9149). After accounting for stable creatinine filtration during diuresis, a change in VD alone was insufficient to elicit a ≥0.3 mg/dl rise in creatinine. Larger estimated decreases in VD were paradoxically associated with improvement in Cr (=-0.18, =0.003). Overall, -3% of the change in eCr was attributable to the change in VD. A ≥0.3 mg/dl rise in eCr was not associated with worsening of KIM-1, NGAL, NAG, or postdischarge survival (>0.05 for all).
During ADHF therapy, increases in serum creatinine are driven predominantly by changes in filtration, with minimal contribution from change in VD.
在治疗急性失代偿性心力衰竭(ADHF)期间,血清肌酐恶化很常见。肌酐增加的一个可能原因是,随着全身水(TBW)围绕固定肌酐质量收缩,利尿引起的肌酐分布容积(VD)变化。我们的目的是更好地了解 ADHF 期间肌酐变化的滤过和非滤过因素。
ROSE-AHF 试验中纳入了基线至 72 小时血清肌酐、净液体输出和尿 KIM-1、NGAL 和 NAG 的患者(n=270)。通过考虑基于体重计算的 TBW 的测量输入和输出,计算 VD 的变化。使用动力学 GFR 方程(Cr),在考虑 VD 变化和非稳态条件后,比较观察到的肌酐(Cr)变化与预测的肌酐变化,以校正 Cr 变化。
仅考虑 VD 的变化时,引起肌酐升高≥0.3mg/dl 的利尿中位数为-7526ml(IQR,-5932 至-9149)。在利尿期间稳定肌酐滤过的情况下,单独的 VD 变化不足以引起肌酐升高≥0.3mg/dl。估计的 VD 较大降幅与 Cr 的改善呈反比(=-0.18,=0.003)。总体而言,eCr 变化的-3%归因于 VD 的变化。eCr 升高≥0.3mg/dl 与 KIM-1、NGAL、NAG 或出院后生存恶化无关(所有 P 值均>0.05)。
在 ADHF 治疗期间,血清肌酐的增加主要由滤过变化引起,而由 VD 变化引起的变化很小。